Freestone Grove Partners LP Takes $8.39 Million Position in ANI Pharmaceuticals, Inc. $ANIP

Freestone Grove Partners LP purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 101,332 shares of the specialty pharmaceutical company’s stock, valued at approximately $8,388,000. Freestone Grove Partners LP owned 0.44% of ANI Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. raised its position in ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares during the last quarter. State Street Corp lifted its holdings in ANI Pharmaceuticals by 2.2% during the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after buying an additional 15,496 shares during the period. UBS Group AG grew its position in shares of ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after buying an additional 185,172 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of ANI Pharmaceuticals by 19.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock valued at $43,399,000 after buying an additional 91,153 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of ANI Pharmaceuticals by 8.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after buying an additional 43,523 shares during the period. Institutional investors own 76.05% of the company’s stock.

Insider Transactions at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the completion of the sale, the vice president owned 74,424 shares in the company, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00. Following the completion of the sale, the chief executive officer owned 344,489 shares of the company’s stock, valued at $25,595,532.70. This represents a 1.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 24,387 shares of company stock valued at $1,947,625. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals Stock Performance

ANIP stock opened at $72.83 on Friday. The firm has a market cap of $1.67 billion, a PE ratio of 15.70 and a beta of 0.44. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The stock has a 50-day moving average price of $79.68 and a 200-day moving average price of $78.65. ANI Pharmaceuticals, Inc. has a 1-year low of $70.15 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the prior year, the company earned $1.80 EPS. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Guggenheim lowered their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Canaccord Genuity Group reduced their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.83.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.